GlassScriptPhysician profile
Hunganh B Bui
NPI 1073576401
$11,937.68
in general payments reported to CMS, 2019-2025
38 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,443 · 2020: $1,984 · 2021: $1,455 · 2022: $1,588 · 2023: $1,855 · 2024: $1,448 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,587.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,365.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,265.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $786.30 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $746.56 | 2019-2024 | Verquvo, Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $525.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $507.01 | 2019-2024 | |
| Pfizer INC. | $501.41 | 2019-2023 | |
| Abbvie INC. | $485.83 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $473.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $450.27 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Paratek Pharmaceuticals, INC. | $421.57 | 2020-2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.11 | 2019-2025 | Xifaxan |
| Mylan Specialty L.P. | $306.51 | 2021-2024 | Yupelri |
| Astellas Pharma US INC | $296.80 | 2019-2025 | Veozah |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $269.19 | 2019-2024 | Eliquis |
| Sumitomo Pharma America, INC. | $214.71 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $169.75 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.27 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $131.25 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $110.12 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $97.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $95.59 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $89.32 | 2019-2025 | Zoryve |
| Viatris Specialty LLC | $79.31 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $58.16 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $57.88 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.04 | 2022 | |
| Radius Health, INC. | $44.65 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $38.62 | 2020-2021 | |
| Allergan, INC. | $36.81 | 2019 | |
| Amarin Pharma, INC. | $31.40 | 2020 | |
| Calliditas Therapeutics US INC. | $27.33 | 2022 | |
| Lundbeck LLC | $22.50 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $17.25 | 2022 | |
| Currax Pharmaceuticals LLC | $15.54 | 2024 | Contrave |
| Inspire Medical Systems, INC. | $14.25 | 2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunganh Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.